

IELSG

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

TRIALS COORDINATION CENTRE: ISTITUTO ONCOLOGICO DELLA SVIZZERA ITALIANA
OSPEDALE SAN GIOVANNI CH-6500 BELLINZONA - SWITZERLAND

E. ZUCCA, A. CONCONI, F. CAVALLI - DATA MANAGER: CRISTINA MORININI

PHONE ++41 91 820 91 11 - ++41 79 50 99 500 FAX ++41 91 820 91 82 - E-MAIL ielsg@ticino.com

NEWSLETTER 6

Bellinzona, November 2000

Dear Colleagues,

at the end of 2000, we would like to summarize in a few lines another year of successful cooperation and, in the meanwhile, we are pleased to invite you to the next IELSG meeting that will take place in Ascona, Switzerland, on May 5-6, 2001.

IELSG 1: Retrospective evaluation of low-grade MALT lymphoma primarily arising at non-gastric sites.

The accrual is closed and the pathological review has been completed.

An oral communication has been presented at the annual ESMO Congress held in Hamburg on October, 2000.

“NON-GASTRIC MALT LYMPHOMAS: A SURVEY OF 369 PATIENTS - THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)”

Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C, Fraternali G, Giardini R, Ponzoni M, Pedrinis E.

A manuscript is in preparation.

IELSG 3: Randomized trial of observation vs chlorambucil after anti-helicobacter therapy in low-grade gastric lymphoma.

The accrual will presumably close shortly. Indeed, due to the low rate of relapses in both cohorts of patients (chlorambucil vs observation), the planned number of patients to be enrolled will not be able to answer the main questions of the study.

The molecular monitoring on 60 enrolled patients has been performed.

An oral communication has been presented at the annual ASCO Conference held in New Orleans, on May 2000.

“INTERIM EVALUATION OF GASTRIC MALT LYMPHOMA RESPONSE TO ANTIBIOTICS IN THE ONGOING LY03 RANDOMIZED COOPERATIVE TRIAL OF OBSERVATION VS. CHLORAMBUCIL AFTER ANTI-HELICOBACTER THERAPY”

E. Zucca, E. Roggero, J. Delchier, P. Smith, C. Copie-bergmann, C. Traullé, S. Cortelazzo, A. J. Ferreri, A. Ambrosetti, G. Pinotti, F. Cavalli, R. L. Souhami: IELSG, Bellinzona, Switzerland; GELA, Paris, France; UKLG, London, UK.

IELSG 4: Prospective randomized trial of chemotherapy vs chemotherapy plus irradiation in diffuse large- cell gastric lymphoma.

The accrual is ongoing. Seventeen patients have been enrolled.

If you are interested to participate to this study, please contact:

Emanuela Marrocco, Data Manager, Hematoncology Department, Istituto Europeo di Oncologia, Milano, Italy

Phone ++39 02 57489536

Fax ++39 02 57489538

E-mail: datamom1b@ieo.it

IELSG 5: Retrospective evaluation of primary testicular lymphomas.

The accrual is closed. The final analysis has been performed and a paper is in preparation.

An abstract has been selected for a **poster presentation** during the next ASH Meeting, that will take place in San Francisco on December, 2000.

“PATTERNS OF SURVIVAL IN PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE TESTIS: AN INTERNATIONAL SURVEY OF 373 PATIENTS”

Zucca E, Conconi A, Mughal TI, Sarris AH, Vitolo U and Gospodarowicz MK on behalf of the International Extranodal Lymphoma Study Group (IELSG).

Abstracts will be submitted to both the European and the American society of Urology

IELSG 6: A phase II study to determine the clinical activity and safety of Rituximab (IDEC- C2B8) in marginal zone B- cell lymphomas (MZLs).

The accrual is open in Switzerland, Italy and France (23 patients enrolled: 19 extranodal MALT lymphomas, 1 nodal MZLs and 3 splenic MZLs).

In August 2000 an interim analysis has been performed: based on the activity observed in the first enrolled patients, the completion of the accrual has been decided. Since in most patients a diagnosis of extranodal MZLs of MALT-type was made, the further accrual will be limited to these patients. An abstract summarizing the results of a preliminary analysis of clinical activity of rituximab in these lymphomas will be submitted to the next ASCO Annual Meeting.

IELSG 7: Retrospective evaluation of central nervous system lymphomas.

A preliminary analysis on 378 cases has been presented. The accrual is closed. The histological review is ongoing.

Three abstracts have been submitted to the 42nd ASH Annual Meeting, on December 2000, in San Francisco.

A. will be presented as oral communication:

“THERAPEUTIC MANAGEMENT OF IMMUNOCOMPETENT PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNLS): ANALYSIS OF AN INTERNATIONAL MULTICENTRE SERIES OF 378 PATIENTS.”

Ferreri AJM, Reni M, Pasini F, Tirelli U, Calderoni A, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Bernardi M, Conroy T, Barbui T, Cavalli F and Blay J-Y.

B. will be presented as poster:

“PREDICTORS OF RESPONSE AND SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNLS): ANALYSIS OF AN INTERNATIONAL MULTICENTRE SERIES OF 378 IMMUNOCOMPETENT PATIENTS.”

Ferreri AJM, Blay J-Y, Pasini F, Spina M, Vavassori V, Ambrosetti A, Calderoni A, Rossi A, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Kaplanskaia I, Orvieto E, Sanchez J, Chevreau C, Camba L, Villa E and Cavalli F.

C. will be presented as poster:

“INTRAOCULAR LYMPHOMA (IOL): TREATMENT AND OUTCOME IN HIV-PATIENTS.”

Ferreri AJM, Blay J-Y, Reni M, Gubkin A, Dell’Oro S, Zucca E, Cortelazzo SF, Ciceri F, Thyss A, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M and Cavalli F.

IELSG 8: Retrospective evaluation of primary intestinal lymphomas.

The accrual is closed and the pathological review has been completed in May 2000.

The final analysis has been performed and a paper has been completing in these days.

IELSG 9: Retrospective evaluation of primary mediastinal large B-cell lymphomas.

The statistical analysis on 426 cases has been performed.

The accrual is closed. The pathological review has been completed.

An abstract has been selected for a **poster presentation** during the next ASH Meeting too:

“PRIMARY MEDIASTINAL LYMPHOMA: A MULTICENTER STUDY BY THE IELSG”
P. Zinzani, M. Martelli, M. Bertini, E. Zucca, on behalf of the International Extranodal Lymphoma Study Group.

IELSG 10: A phase II study of CHOP, with intrathecal methotrexate followed by radiotherapy, in patients with primary testicular non-Hodgkin’s lymphoma.

The study protocol has been completed. **The patient enrollment will start in**

December. All interested centers may ask for the study protocol to the IELSG Coordinating Center in Bellinzona

Data-Managers:

- Cristina Morinini, IELSG Coordinating Center, Bellinzona, Switzerland, ielsg@ticino.com
- Ofelia Mesina, MD Anderson Cancer Center, Houston, USA, omesina@mail.manderson.org

IELSG 11: Retrospective evaluation of cutaneous B-cell lymphomas.

The accrual is ongoing: 114 cases have been so far registered. The pathological review is forthcoming.

If you have cases to enroll patients, please contact:

Dr. Elena Oldani, Data Manager, Hematology Division, Ospedali Riuniti, Bergamo, Italy

Phone +39 035 269.492/3

Fax +39 035 266.147

e-mail: ematologia@cyberg.it

IELSG 13: Prevalence of hepatitis C virus (HCV) infection among non- Hodgkin lymphoma (NHL) patients - feasibility study.

The sample collection has been started on November 2000. For pilot study, 50 patients (and a corresponding number of controls) from each participating center will be enrolled over approximately 6 months. At the end of this preliminary phase study, the recruitment of additional patients will start in all interested institutions. A total number of at least 1000 patients and 1000 controls are expected to enter the international multicentric phase of the study within 12-18 additional months.

Participating centers to the pilot study:

- Switzerland Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni, Bellinzona (Emanuele Zucca)
- Spain Servicio de Hematología, Clínic Hospital Universitari, Barcelona (Emilio Montserrat)
- United Kingdom CRC Wessex Medical Oncology Unit, Southampton General Hospital, Southampton (Peter WM Johnson)

Data-Manager: Cristina Morinini, IELSG Coordinating Center, Bellinzona, Switzerland, ielsg@ticino.com.

The next IELSG meeting will take place in Ascona, Switzerland, on May 5- 6, 2001.

Program, participation fee, travel arrangement and further details will be diffused as soon as possible. Please reserve the date.

Best regards

E. Zucca, A. Conconi, F. Cavalli, C. Morinini